Curcumin enhances the effectiveness of cisplatin by suppressing CD133+ cancer stem cells in laryngeal carcinoma treatment

Zhang,Hejia; Yu,Tianyu; Wen,Lianji; Wang,Hui; Fei,Dan; Jin,Chunshun

doi:10.3892/etm.2013.1297

Curcumin enhances the effectiveness of cisplatin by suppressing CD133+ cancer stem cells in laryngeal carcinoma treatment

Authors:
- Hejia Zhang
- Tianyu Yu
- Lianji Wen
- Hui Wang
- Dan Fei
- Chunshun Jin
View Affiliations

Affiliations: Department of Otorhinolaryngology, Second Hospital of Jilin Uinversity, Changchun, Jilin 130041, P.R. China, Department of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Ultrasonography, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: September 13, 2013 https://doi.org/10.3892/etm.2013.1297
Pages: 1317-1321

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemoresistance is one of the major barriers to chemotherapeutic treatment and it has been established that CD133+ cancer stem cells are responsible for drug resistance in laryngeal carcinoma. In the present study, curcumin and cisplatin were used as a combined treatment to induce the sensitivity of CD133+ cancer stem cells to chemotherapeutic agents and to enhance therapeutic effectiveness. The results revealed that in untreated and cisplatin-treated HEp-2 cell groups, the percentage of CD133+ cells was 4.50 and 6.89%, respectively. However, in the combined treatment group, the percentage of CD133+ cells was markedly reduced to 1.49%, indicating that curcumin may increase the sensitivity of CD133+ cells to cisplatin, leading to the suppression of chemoresistance in HEp-2 cells. Furthermore, the expression of ATP-binding cassette sub‑family G member 2 (ABCG2), which is an important gene for chemoresistance, was demonstrated to be reduced in CD133+ cancer stem cells following combined treatment. These results suggest that the combined application of curcumin with chemotherapeutic drugs may be a reliable and effective approach for the treatment of laryngeal carcinoma.

View Figures

View References

1.	Spillane JB and Henderson MA: Cancer stem cells: a review. ANZ J Surg. 77:464–468. 2007. View Article : Google Scholar : PubMed/NCBI
2.	Fillmore CM and Kuperwasser C: Human breast cancer cell lines contain stem-like cells that self-renew, give rise to pheno-typically diverse progeny and survive chemotherapy. Breast Cancer Res. 10:R252008. View Article : Google Scholar : PubMed/NCBI
3.	Yang JP, Liu Y, Zhong W, Yu D, Wen LJ and Jin CS: Chemoresistance of CD133⁺ cancer stem cells in laryngeal carcinoma. Chin Med J (Engl). 124:1055–1060. 2011.PubMed/NCBI
4.	Zhou L, Wei X, Cheng L, Tian J and Jiang JJ: CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope. 117:455–460. 2007. View Article : Google Scholar : PubMed/NCBI
5.	Sharma BK, Manglik V, O’Connell M, et al: Clonal dominance of CD133⁺ subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma. Int J Oncol. 41:1570–1576. 2012.
6.	Yin T, Wei H, Gou S, et al: Cancer stem-like cells enriched in panc-1 spheres possess increased migration ability and resistance to gemcitabine. Int J Mol Sci. 12:1595–1604. 2011. View Article : Google Scholar : PubMed/NCBI
7.	McWhinney SR, Goldberg RM and McLeod HL: Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 8:10–16. 2009. View Article : Google Scholar
8.	Price KA and Cohen EE: Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol. 13:35–46. 2012. View Article : Google Scholar : PubMed/NCBI
9.	Ammon HP and Wahl MA: Pharmacology of Curcuma longa. Planta Med. 57:1–7. 1991.
10.	Reuter S, Eifes S, Dicato M, Aggarwal BB and Diederich M: Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol. 76:1340–1351. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Teiten MH, Eifes S, Dicato M and Diederich M: Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel). 2:128–162. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Li L, Braiteh FS and Kurzrock R: Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 104:1322–1331. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Yamano Y, Uzawa K, Saito K, et al: Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. Int J Cancer. 126:437–449. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Visvader JE and Lindeman GJ: Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 10:717–728. 2012. View Article : Google Scholar : PubMed/NCBI
15.	Bertolini G, Roz L, Perego P, et al: Highly tumorigenic lung cancer CD133⁺ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA. 106:16281–16286. 2009.PubMed/NCBI
16.	de Jonge-Peeters SD, Kuipers F, de Vries EG and Vellenga E: ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol. 62:214–226. 2007.PubMed/NCBI
17.	Sarkadi B, Ozvegy-Laczka C, Német K and Váradi A: ABCG2 - a transporter for all seasons. FEBS Lett. 567:116–120. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Zhou S, Schuetz JD, Bunting KD, et al: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 7:1028–1034. 2001. View Article : Google Scholar : PubMed/NCBI
19.	An Y and Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 5:1529–1542. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA and Brenner MK: A distinct ‘side population’ of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle. 4:203–205. 2005.